Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.

Woosley RL, Myers RT, Goodsaid F.

Clin Pharmacol Ther. 2010 May;87(5):530-3. doi: 10.1038/clpt.2010.27. Review.

PMID:
20407457
2.

How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.

Perakslis ED, Van Dam J, Szalma S.

Clin Pharmacol Ther. 2010 May;87(5):614-6. doi: 10.1038/clpt.2010.21. Epub 2010 Apr 7. Review. No abstract available.

PMID:
20376001
3.

Arguments against precompetitive collaboration.

Vargas G, Boutouyrie B, Ostrowitzki S, Santarelli L.

Clin Pharmacol Ther. 2010 May;87(5):527-9. doi: 10.1038/clpt.2010.30. Review. No abstract available.

PMID:
20407456
4.

The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.

Wagner JA, Prince M, Wright EC, Ennis MM, Kochan J, Nunez DJ, Schneider B, Wang MD, Chen Y, Ghosh S, Musser BJ, Vassileva MT.

Clin Pharmacol Ther. 2010 May;87(5):539-42. doi: 10.1038/clpt.2009.227. Review.

PMID:
20407460
5.

Open-minded to open innovation and precompetitive collaboration.

Wagner JA.

Clin Pharmacol Ther. 2010 May;87(5):511-5. doi: 10.1038/clpt.2010.39. Review. No abstract available.

PMID:
20407451
6.

Examining Manufacturing Readiness for Breakthrough Drug Development.

Dye E, Sturgess A, Maheshwari G, May K, Ruegger C, Ramesh U, Tan H, Cockerill K, Groskoph J, Lacana E, Lee S, Miksinski SP.

AAPS PharmSciTech. 2016 Jun;17(3):529-38. doi: 10.1208/s12249-015-0455-1. Epub 2015 Nov 25. Review. No abstract available.

PMID:
26608693
7.

Clinical utility of the Food and Drug Administration Electrocardiogram Warehouse: a paradigm for the critical pathway initiative.

Cabell CH, Noto TC, Krucoff MW.

J Electrocardiol. 2005 Oct;38(4 Suppl):175-9. Review.

PMID:
16226096
8.

The future is much closer collaboration between the pharmaceutical industry and academic medical centers.

Vallance P, Williams P, Dollery C.

Clin Pharmacol Ther. 2010 May;87(5):525-7. doi: 10.1038/clpt.2010.29. Review. No abstract available.

PMID:
20407455
9.

Paving the critical path: how can clinical pharmacology help achieve the vision?

Lesko LJ.

Clin Pharmacol Ther. 2007 Feb;81(2):170-7. Review.

PMID:
17259944
10.

Drug development: from concept to marketing!

Tamimi NA, Ellis P.

Nephron Clin Pract. 2009;113(3):c125-31. doi: 10.1159/000232592. Epub 2009 Aug 12. Review.

11.

Trends in risks associated with new drug development: success rates for investigational drugs.

DiMasi JA, Feldman L, Seckler A, Wilson A.

Clin Pharmacol Ther. 2010 Mar;87(3):272-7. doi: 10.1038/clpt.2009.295. Epub 2010 Feb 3. Review.

PMID:
20130567
12.

The FDA critical path initiative and its influence on new drug development.

Woodcock J, Woosley R.

Annu Rev Med. 2008;59:1-12. doi: 10.1146/annurev.med.59.090506.155819. Review.

PMID:
18186700
13.

ASCPT Task Force for advancing pharmacometrics and integration into drug development.

Goldberger MJ, Singh N, Allerheiligen S, Gobburu JV, Lalonde R, Smith B, Ryder S, Yozviak A.

Clin Pharmacol Ther. 2010 Aug;88(2):158-61. doi: 10.1038/clpt.2010.141. Review. Erratum in: Clin Pharmacol Ther. 2010 Dec;88(6):883.. Allerheiligan, S [corrected to Allerheiligen, S].

PMID:
20648032
14.

Drug discovery in the next decade: innovation needed ASAP.

Bennani YL.

Drug Discov Today. 2011 Sep;16(17-18):779-92. doi: 10.1016/j.drudis.2011.06.004. Epub 2011 Jun 15. Review.

PMID:
21704185
15.

Network biology as a new approach to drug discovery.

Lowe JA, Jones P, Wilson DM.

Curr Opin Drug Discov Devel. 2010 Sep;13(5):524-6. Review.

PMID:
20812143
16.

Productivity shortfalls in drug discovery: contributions from the preclinical sciences?

Williams M.

J Pharmacol Exp Ther. 2011 Jan;336(1):3-8. doi: 10.1124/jpet.110.171751. Epub 2010 Aug 25. Review.

17.

Pharmacological mechanism-based drug safety assessment and prediction.

Abernethy DR, Woodcock J, Lesko LJ.

Clin Pharmacol Ther. 2011 Jun;89(6):793-7. doi: 10.1038/clpt.2011.55. Epub 2011 Apr 13. Review.

PMID:
21490594
18.

Computational toxicology approaches at the US Food and Drug Administration.

Yang C, Valerio LG Jr, Arvidson KB.

Altern Lab Anim. 2009 Nov;37(5):523-31. Review.

PMID:
20017581
19.

Can open-source drug R&D repower pharmaceutical innovation?

Munos B.

Clin Pharmacol Ther. 2010 May;87(5):534-6. doi: 10.1038/clpt.2010.26. Review.

PMID:
20407458
20.

The value of drug repositioning in the current pharmaceutical market.

Tobinick EL.

Drug News Perspect. 2009 Mar;22(2):119-25. doi: 10.1358/dnp.2009.22.2.1303818. Review.

PMID:
19330170

Supplemental Content

Support Center